[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100578292":3},{"organization":4,"outcomesModule":7,"designInfo":34,"detailedDescription":43,"studyPopulation":11,"armGroups":44,"interventions":56,"overallOfficials":66,"centralContacts":70,"locations":79,"responsibleParty":274,"collaborators":11,"id":276,"slug":277,"hasResults":278,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":11,"eligibilityCriteria":282,"healthyVolunteers":283,"sex":284,"minAge":285,"maxAge":286,"enrollmentInfo":287,"targetDuration":11,"studyType":290,"phases":291,"briefSummary":293,"conditions":294,"keywords":11,"overallStatus":82,"whyStopped":11,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":305},{"fullName":5,"class":6},"Eli Lilly and Company","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":20,"otherOutcomes":11},[9,13,15,18],{"measure":10,"description":11,"timeFrame":12},"Number of Participants with One or More Serious Adverse Event(s) (SAEs) Part A",null,"Baseline to Week 48",{"measure":14,"description":11,"timeFrame":12},"Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs) Part A",{"measure":16,"description":11,"timeFrame":17},"Number of Participants with One or More SAEs Part B","Baseline to Week 61",{"measure":19,"description":11,"timeFrame":17},"Number of Participants with One or More TEAEs Part B",[21,23,25,27,29,32],{"measure":22,"description":11,"timeFrame":12},"Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4006896 ARC-Associated Antisense Part A",{"measure":24,"description":11,"timeFrame":17},"PK: Cmax of LY4006896 ARC-Associated Antisense Part B",{"measure":26,"description":11,"timeFrame":12},"PK: Area Under the Concentration versus Time Curve (AUC) of LY4006896 ARC-Associated Antisense Part A",{"measure":28,"description":11,"timeFrame":17},"PK: AUC of LY4006896 ARC-Associated Antisense Part B",{"measure":30,"description":31,"timeFrame":17},"Effect of LY4006896 on Aggregation-Competent Alpha-Synuclein in Skin Part B","Alpha-synuclein seed amplification positivity",{"measure":33,"description":31,"timeFrame":17},"Effect of LY4006896 on Aggregation-Competent Alpha-Synuclein in Cerebrospinal Fluid (CSF) Part B",{"allocation":35,"interventionModel":36,"interventionModelDescription":11,"primaryPurpose":37,"observationalModel":11,"timePerspective":11,"maskingInfo":38},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":39,"maskingDescription":40,"whoMasked":41},"SINGLE","This is a single-blind study where the participants, investigator, and site personnel (except pharmacy staff) are blinded to study intervention.",[42],"PARTICIPANT","The screening period will be up to 120 days for participants with Parkinson's disease who receive up to 4 doses, and up to 35 days for healthy participants who receive 1 dose. The treatment and follow-up duration will be up to 61 weeks for participants with Parkinson's disease, and 48 weeks for healthy participants.\n\nThe total study duration will be up to 78 weeks for participants with Parkinson's disease, and 53 weeks for healthy participants.",[45,51],{"label":46,"type":47,"description":48,"interventionNames":49},"Part A LY4006896 + Placebo","EXPERIMENTAL","Healthy participants will receive a single escalating dose of LY4006896 and matching placebo.",[50],"Drug: LY4006896",{"label":52,"type":47,"description":53,"interventionNames":54},"Part B LY4006896 + Placebo","Participants with Parkinson's disease will receive multiple doses of LY4006896 and matching placebo.",[55],"Drug: Placebo",[57,62],{"type":58,"name":59,"description":60,"armGroupLabels":61,"otherNames":11},"DRUG","LY4006896","Administered intravenously (IV)",[46],{"type":58,"name":63,"description":64,"armGroupLabels":65,"otherNames":11},"Placebo","Administered IV",[52],[67],{"name":68,"affiliation":5,"role":69},"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC\u002FGMT - 5 hours, EST)","STUDY_DIRECTOR",[71,76],{"name":72,"role":73,"phone":74,"phoneExt":11,"email":75},"Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or","CONTACT","1-317-615-4559","LillyTrials@Lilly.com",{"name":77,"role":73,"phone":11,"phoneExt":11,"email":78},"Physicians interested in becoming principal investigators please contact","clinical_inquiry_hub@lilly.com",[80,100,109,120,134,148,162,175,185,200,215,231,245,261],{"facility":81,"status":82,"city":83,"state":84,"zip":85,"country":86,"countryCode":87,"cosmosGeoPoint":88,"geoPoint":93,"contacts":94},"Collaborative Neuroscience Network - CNS","RECRUITING","Los Alamitos","California","90720","United States","US",{"type":89,"coordinates":90},"Point",[91,92],-118.07256,33.80307,{"lat":92,"lon":91},[95,97],{"name":11,"role":73,"phone":96,"phoneExt":11,"email":11},"844-424-9494",{"name":98,"role":99,"phone":11,"phoneExt":11,"email":11},"Steven Reynolds","PRINCIPAL_INVESTIGATOR",{"facility":81,"status":82,"city":83,"state":84,"zip":85,"country":86,"countryCode":87,"cosmosGeoPoint":101,"geoPoint":103,"contacts":104},{"type":89,"coordinates":102},[91,92],{"lat":92,"lon":91},[105,107],{"name":11,"role":73,"phone":106,"phoneExt":11,"email":11},"562-742-7116",{"name":108,"role":99,"phone":11,"phoneExt":11,"email":11},"Omid Omidvar",{"facility":110,"status":111,"city":112,"state":113,"zip":114,"country":86,"countryCode":87,"cosmosGeoPoint":115,"geoPoint":119,"contacts":11},"K2 Medical Research, LLC","COMPLETED","Maitland","Florida","32751",{"type":89,"coordinates":116},[117,118],-81.36312,28.62778,{"lat":118,"lon":117},{"facility":121,"status":82,"city":122,"state":113,"zip":123,"country":86,"countryCode":87,"cosmosGeoPoint":124,"geoPoint":128,"contacts":129},"Aqualane Clinical Research","Naples","34105",{"type":89,"coordinates":125},[126,127],-81.79596,26.14234,{"lat":127,"lon":126},[130,132],{"name":11,"role":73,"phone":131,"phoneExt":11,"email":11},"239-529-6780",{"name":133,"role":99,"phone":11,"phoneExt":11,"email":11},"William Justiz",{"facility":135,"status":82,"city":136,"state":113,"zip":137,"country":86,"countryCode":87,"cosmosGeoPoint":138,"geoPoint":142,"contacts":143},"Charter Research","Orlando","32803",{"type":89,"coordinates":139},[140,141],-81.37924,28.53834,{"lat":141,"lon":140},[144,146],{"name":11,"role":73,"phone":145,"phoneExt":11,"email":11},"407-337-1000",{"name":147,"role":99,"phone":11,"phoneExt":11,"email":11},"Diana Balsalobre",{"facility":149,"status":82,"city":150,"state":113,"zip":151,"country":86,"countryCode":87,"cosmosGeoPoint":152,"geoPoint":156,"contacts":157},"Progressive Medical Research","Port Orange","32127",{"type":89,"coordinates":153},[154,155],-80.99561,29.13832,{"lat":155,"lon":154},[158,160],{"name":11,"role":73,"phone":159,"phoneExt":11,"email":11},"386-304-7070",{"name":161,"role":99,"phone":11,"phoneExt":11,"email":11},"Alexander White",{"facility":110,"status":82,"city":163,"state":113,"zip":164,"country":86,"countryCode":87,"cosmosGeoPoint":165,"geoPoint":169,"contacts":170},"The Villages","32159",{"type":89,"coordinates":166},[167,168],-81.95994,28.93408,{"lat":168,"lon":167},[171,173],{"name":11,"role":73,"phone":172,"phoneExt":11,"email":11},"321-278-5590",{"name":174,"role":99,"phone":11,"phoneExt":11,"email":11},"Craig Curtis",{"facility":135,"status":82,"city":163,"state":113,"zip":176,"country":86,"countryCode":87,"cosmosGeoPoint":177,"geoPoint":179,"contacts":180},"32162-2698",{"type":89,"coordinates":178},[167,168],{"lat":168,"lon":167},[181,183],{"name":11,"role":73,"phone":182,"phoneExt":11,"email":11},"352-775-1000",{"name":184,"role":99,"phone":11,"phoneExt":11,"email":11},"Jeffrey Norton",{"facility":186,"status":82,"city":187,"state":188,"zip":189,"country":86,"countryCode":87,"cosmosGeoPoint":190,"geoPoint":194,"contacts":195},"QUEST Research Institute","Farmington Hills","Michigan","48334",{"type":89,"coordinates":191},[192,193],-83.37716,42.48531,{"lat":193,"lon":192},[196,198],{"name":11,"role":73,"phone":197,"phoneExt":11,"email":11},"248-957-8940",{"name":199,"role":99,"phone":11,"phoneExt":11,"email":11},"Aaron Ellenbogen",{"facility":201,"status":82,"city":202,"state":203,"zip":204,"country":86,"countryCode":87,"cosmosGeoPoint":205,"geoPoint":209,"contacts":210},"PPD Development, LP","Austin","Texas","78744",{"type":89,"coordinates":206},[207,208],-97.74306,30.26715,{"lat":208,"lon":207},[211,213],{"name":11,"role":73,"phone":212,"phoneExt":11,"email":11},"877-773-3707",{"name":214,"role":99,"phone":11,"phoneExt":11,"email":11},"Sabrina Merchant",{"facility":216,"status":217,"city":218,"state":219,"zip":220,"country":86,"countryCode":87,"cosmosGeoPoint":221,"geoPoint":225,"contacts":226},"Evergreen Health Research","NOT_YET_RECRUITING","Kirkland","Washington","98034",{"type":89,"coordinates":222},[223,224],-122.20874,47.68149,{"lat":224,"lon":223},[227,229],{"name":11,"role":73,"phone":228,"phoneExt":11,"email":11},"425-899-5385",{"name":230,"role":99,"phone":11,"phoneExt":11,"email":11},"Pinky Agarwal",{"facility":232,"status":217,"city":233,"state":219,"zip":234,"country":86,"countryCode":87,"cosmosGeoPoint":235,"geoPoint":239,"contacts":240},"Inland Northwest Research","Spokane","99202",{"type":89,"coordinates":236},[237,238],-117.42908,47.65966,{"lat":238,"lon":237},[241,243],{"name":11,"role":73,"phone":242,"phoneExt":11,"email":11},"509-960-2818",{"name":244,"role":99,"phone":11,"phoneExt":11,"email":11},"Jason Aldred",{"facility":246,"status":82,"city":247,"state":11,"zip":248,"country":249,"countryCode":250,"cosmosGeoPoint":251,"geoPoint":255,"contacts":256},"P-One Clinic","Hachiōji","192-0071","Japan","JP",{"type":89,"coordinates":252},[253,254],139.32389,35.65583,{"lat":254,"lon":253},[257,259],{"name":11,"role":73,"phone":258,"phoneExt":11,"email":11},"81120023812",{"name":260,"role":99,"phone":11,"phoneExt":11,"email":11},"Kenichi Furihata",{"facility":262,"status":82,"city":263,"state":11,"zip":264,"country":249,"countryCode":250,"cosmosGeoPoint":265,"geoPoint":269,"contacts":270},"Oita University Hospital","Yufu","879-5593",{"type":89,"coordinates":266},[267,268],131.37829,33.1956,{"lat":268,"lon":267},[271,272],{"name":11,"role":73,"phone":258,"phoneExt":11,"email":11},{"name":273,"role":99,"phone":11,"phoneExt":11,"email":11},"Naoto Uemura",{"type":275,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100578292","phase-1-a-study-of-ly4006896-in-healthy-participants-and-participants-with-parkinsons-disease-100578292",false,"NCT06809400","A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease","A Single-Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4006896 in Healthy Participants and Participants With Parkinson's Disease","Inclusion Criteria:\n\nPart A Single Ascending Dose (SAD) and B Multiple Dose (MD)\n\n* Have a body mass index within the range of 18 to 34 kilogram per square meter (kg\u002Fm²) (inclusive).\n* For Japanese participants: To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Japanese descent and born in Japan.\n* Have venous access sufficient to allow for blood sampling or administration of study intervention for IV administration, or both.\n\nPart A (SAD) Only\n\n* Participant must be 30 to 85 years of age (inclusive), at the time of signing the informed consent\n* Are overtly healthy\n* For Chinese participants: To qualify as Chinese for this study, all 4 of the participant's biological grandparents must be exclusive Chinese descent and born in China.\n\nPart B (MD) Only\n\n* Participant must be 40 to 85 years of age (inclusive), at the time of signing the informed consent\n* Diagnosis of Parkinson's disease per United Kingdom (UK) Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria.\n* If presently untreated for Parkinson's disease, clinical status is not expected to require changes in symptomatic treatment within 52 weeks from baseline.\n* If presently being treated for Parkinson's disease, receiving a stable dose of symptomatic dopaminergic therapy, including monoamine oxidase-B inhibitor, levodopa\u002Fcarbidopa or dopamine agonist for at least 90 days prior to baseline and not expected to change within 52 weeks.\n* Have a Montreal Cognitive Assessment (MoCA) score of greater than or equal to (≥) 24.\n\nExclusion Criteria:\n\nPart A (SAD) and B (MD)\n\n* Have significant neurological disease affecting the central nervous system (CNS) (other than Parkinson's disease in Part B cohorts) that may affect the participant's ability to complete the study.\n* Have a history or presence of serious or unstable illnesses or conditions that, in the investigator's opinion, could interfere with the analyses in this study, or increase risk for study intervention administration, or result in a participant's life expectancy of less than 24 months.\n* Have known allergies to LY4006896, related compounds, or any components of the formulation, or history of allergic reactions to any transferrin receptor antibodies.\n* Have significant allergies to humanize monoclonal antibodies.\n* Have clinically significant multiple or severe drug allergies (including, but not limited to, erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, or exfoliative dermatitis); or intolerance to topical corticosteroids, or severe posttreatment hypersensitivity reactions.\n* Have history or presence of uncontrolled asthma, significant autoimmune disease, hereditary angioedema, or known history of common variable immune deficiency.\n* Evidence of clinically significant anemia.\n\nPart A (SAD) Only\n\n* Have an abnormal blood pressure or pulse rate, or both, as determined by the investigator, or a preexisting history of hypertension.\n\nPart B (MD) Only\n\n* Have an abnormal blood pressure or pulse rate, or both, as determined by the investigator, or have uncontrolled hypertension, defined as a systolic blood pressure greater than (\\>) 150 mmHg or a diastolic blood pressure \\>95 mmHg at Screening or Treatment Visits.\n* Have an implanted deep brain stimulation (DBS) system or any other implanted neurostimulation device (including but not limited to spinal cord stimulation, vagus nerve stimulation or investigational neuromodulation devices)\n* Are receiving continuous infusion therapy with anti-parkinsonian medications, including but not limited to subcutaneous foslevodopa-foscarbidopa, subcutaneous apomorphine, or intraduodenal\u002Fintestinal levodopa formulations\n\nDiagnostic assessments\n\n* Hemoglobin A1c 6.5 percent (%) or higher",true,"ALL","30 Years","85 Years",{"count":288,"type":289},90,"ESTIMATED","INTERVENTIONAL",[292],"PHASE1","The purpose of this study is to generate evidence of the safety, tolerability, and pharmacokinetics\u002Fpharmacodynamics of IV LY4006896 compared with placebo in healthy participants and participants with Parkinson's disease.",[295],"Parkinson Disease","2026-10-08",{"date":298,"type":299},"2026-10-14","ACTUAL",{"date":301,"type":299},"2025-02-18",{"date":303,"type":289},"2028-10",{"name":5,"class":6},14]